Black Bird Biotech Inc   (DGDM)
Other Ticker:  
Price: $0.0000 $0.00 %
Day's High: 0.00 Week Perf:
Day's Low: $ 0.00 30 Day Perf:
Volume (M): 0 52 Wk High: $ 0.00
Volume (M$): $ 0 52 Wk Avg: $0.00
Open: $0.00 52 Wk Low: $0.00

 Market Capitalization (Millions $) -
 Shares Outstanding (Millions) 1,918
 Employees 1
 Revenues (TTM) (Millions $) 0
 Net Income (TTM) (Millions $) -1
 Cash Flow (TTM) (Millions $) 0
 Capital Exp. (TTM) (Millions $) 0

Black Bird Biotech Inc
Aside from its “EFT-Phone”, EFT distributes 25 nutritional products, 18 personal care products, an environmentally friendly automotive product, an environmentally friendly house cleaner and a portable drinking container which contains a filter to remove impurities.

   Company Address: 11961 Hilltop Road Argyle 76226 TX
   Company Phone Number: 223-4204   Stock Exchange / Ticker: DGDM


Stock Performances by Major Competitors

5 Days Decrease / Increase
• View Complete Report

Black Bird Biotech Inc

Black Bird Biotech Inc's Revenue Plummets in Q3 2023, signalling potential trouble for the biotech industry

In the fiscal third quarter of 2023, Black Bird Biotech Inc achieved a break-even position of $0.00 per share. This is the same as the previous year and the prior financial reporting period. However, the company experienced a significant drop in revenue, decreasing to $0.00 million from $0.03 million compared to the same period last year, and sequentially from $0.01 million.
Despite the decrease in revenue, the Miscellaneous Manufacturing industry as a whole saw an improvement in revenue in the third quarter of 2023. This indicates that Black Bird Biotech's revenue drop may be specific to the company rather than an industry-wide trend.

Black Bird Biotech Inc

Black Bird Biotech Inc Faces Devastating Revenue Slide in Second Quarter of 2023, Underperforming the Miscellaneous Manufacturing Sector

Black Bird Biotech Inc, a company operating in the Miscellaneous Manufacturing sector, recently reported its financial performance for the second quarter of 2023. The company achieved breakeven with zero earnings per share (EPS) compared to the previous year and the preceding quarter. While the revenue saw a significant decline from the corresponding quarter a year ago, it showed sequential improvement. This article will analyze the key financial aspects of Black Bird Biotech Inc's performance for the second quarter of 2023 and discuss its implications for the company's future.
Revenue Performance:
During the second quarter of 2023, Black Bird Biotech Inc witnessed a sharp decline of -58.239% in revenue, with figures dropping from $0.03 million in the corresponding quarter a year prior to $0.01 million. However, on a sequential basis, there was a substantial surge of 74.976% from $0.01 million. This slump in business performance is concerning when compared to the revenue gain of the broader Miscellaneous Manufacturing sector during the same period.

Black Bird Biotech Inc

Black Bird Biotech Inc Plunges into Financial Abyss with a Dramatic 46.493% Revenue Dip in Q1 2023

Black Bird Biotech Inc, a publicly-traded company, recently announced their financial results for the first quarter of 2023. The most significant information from the announcement is that the company reached zero gain per share, compared to its previous year, and from the previous reporting period. The revenue also declined significantly by -46.493 % to $0.01 million from $0.01 million in the comparable reporting period a year prior. Also, sequentially, the revenue tumbled by -38.861 % from $0.01 million. Additionally, in the first quarter of 2023, Black Bird Biotech Inc reported a net loss of $-0.267 million, instead of a deficit of $-0.670 million in the comparable reporting period a year ago.
These results suggest that Black Bird Biotech Inc is facing a challenging financial situation. The company's revenue has decreased, and the absence of any gain per share indicates a lack of profitability. The net loss also means that the company is operating at a loss, which is not sustainable in the long term. However, the company did manage to reduce its deficit from the same quarter in the previous year, which may indicate that they are taking steps to control costs and improve efficiency.


Black Bird Biotech Inc's Segments
• View Complete Report


About us


CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com